Skip to main content

Identification of Small Molecule Inhibitors Targeting COUP-TFII


Prostate cancer is the second most common cancer affecting males in the United States. Hormone therapy has been widely used for prostate cancer treatment, such as androgen deprivation and targeting androgen receptor with small molecules. However, under long-term treatment, patients develop castration-resistant prostate cancer (CRPC) and eventually die. Therefore, it’s urgent to discover novel therapeutic targets to improve prostate cancer treatment. In 2013, the Tsai group identified that COUP-TFII, an orphan nuclear receptor whose overexpression involving in multiple diseases, can serve as a potential drug target for prostate cancer. Recently, the Tsai group further developed novel small molecule inhibitors, CIA1 and CIA2, directly targeting COUPTF-II for prostate cancer treatment.

CIA1 and CIA2 were obtained through a high-throughput screening. They are specific inhibitors targeting COUP-TFII: i) The inhibitors reduce the prostate cell growth while having little effect on cells lacking COUP-TFII. Ii) CIA1 and CIA2 can inhibit the COUP-TFII-activated gene expression and promote the COUP-TFII-repressed gene expression, which were not observed when COUP-TFII was silenced. iii) An RNA-seq analysis showed the similar genome-wide expression profiling of COUP-TFII target genes comparing the CIA1 treated group and the COUP-TFII knockdown group.

A cellular thermal shift assay (CETSA) and biotin-streptavidin pulldown study were performed to further verify that the inhibitors directly interact with COUP-TFII. Furthermore, either W249A or F253A mutation in the ligand binding domain (LBD) can substantially decrease the potency of these inhibitors, demonstrating CIA1 and CIA2 directly bind to COUP-TFII through the ligand binding pocket. Additionally, these inhibitors showed unappreciable binding affinities to other nuclear receptors sharing similar structures based on a pulldown assay, indicating the specificity of these COUP-TFII inhibitors.


Moreover, the inhibitors showed considerable inhibition activity in various prostate cancer cells while barely affecting normal prostate cells. For the in vivo activities, the inhibitors are capable of inducing significant tumor growth inhibition in both xenograft and PDX models without appreciable toxicity in mice. Particularly, not limited to the AR-sensitive tumors, the inhibitors showed good tumor growth inhibition in AR-negative, ARv7-dependent, and AR-null models. This provides a broad potential clinical application in the future.

Previous studies have demonstrated that COUP-TFII can regulate gene expression by recruiting other transcription regulators. Indeed, some transcription regulators interacting with COUP-TFII were impaired after CIA1 treatment. Only FOXA1 knockdown showed the inhibition of prostate cancer cell growth, indicating that COUP-TFII maybe recruit FOXA1 to regulate gene expression and promote prostate cancer cell growth. Further comprehensive mechanism studies disclosed that CIA1 could disrupt the interaction between COUP-TFII and FOXA1, leading to changes in target gene expression.

Although the PK and potency of the inhibitors still need to be further optimized, this study suggests that targeting COUPTF-II with small molecule inhibitors provides a potential avenue to treat prostate cancer and other diseases caused by overexpression of COUP-TFII.

Reference:
1. Qin, J. et al. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature 493, 236–240 (2013).
2. Wang L. et al. Small-molecule inhibitor targeting orphan nucler receptor COUP-TFII for prostate cancer treatment. Sci. Adv. 2020 DOI: 10.1126/sciadv.aaz8031



Comments

Post a Comment

Popular posts from this blog

Lysine-Targeted Covalent Inhibitors Gaining Traction

In the past decade, targeted covalent inhibitors (TCIs) has experienced a resurgence due to its sustained target engagement and improved proteome-wide selectivity. Currently, targeting cysteine residues with acrylamides and other α, β-unsaturated carbonyl compounds is the predominant strategy in TCI development. Although lysine is more prevalent than cysteine and possesses lower mutation rates, lysine has been much less frequently considered and more challenging as a residue targeted by TCIs due to its low nucleophilicity. Recently, Jack Taunton and his colleagues reveled their two related work in JACS .   Based on the co-crystal structure of Hsp90 with a reversible inhibitor PU-H71, they designed two arylsulfonyl fluorides 1 and 2 and co-incubated them with Hsp90 protein (Figure 1a, b). Mass spectrometry detected the formation of a 1:1 covalent adduct. Mutation of Lys58 to arginine abrogated the covalent modification, indicating that the TCI selectively modified Lys58 (Fig...
Post a Comment
Read more

Multiple Postdoc and Technician Positions Available at Baylor College of Medicine

  Multiple postdoc and technician positions are available in Dr. Jin Wang’s group in the Department of Pharmacology and Chemical Biology at Baylor College of Medicine (BCM). BCM is located in the world largest medical center and has access to enormous biomedical resources. The research in the Wang lab is highly interdisciplinary and translational. The Wang lab has both chemistry and biology operations. For chemistry work, we have 17 chemical fume hoods, 4 ISCO combiflash chromatography systems, Agilent analytical LC-MS, Agilent preparative HPLC with auto-purification, and Genevac high throughput solvent evaporation, along with convenient access to 600 and 800 MHz NMR. For biology work, we have common equipment for biochemistry, molecular and cell biology, including tissue culture hoods, RT-PCR, plate reader, and imaging plate reader, and perform animal work to evaluate the efficacy of the experimental therapeutics developed in the group. In addition, we recently acquired a state-...
Post a Comment
Read more

RIPK2 PROTAC Burns up the Bridges between PK and PD

GlaxoSmithKline (GSK) previously reported a series of RIPK2 PROTACs with various E3 ligase binders (Figure 1). These PROTACs can degrade RIPK2 potently and efficiently in a concentration-dependent manner (Figure1). However, their poor solubility and high microsomal clearance limited their in vivo applications. To develop a RIPK2 degrader suitable for  in vivo  applications, the GSK group identified another IAP based RIPK2 PROTAC4 that is significantly different from PROTAC2, possessing a different RIPK2 binder, IAP ligase binder and linker (Figure2). PTROTAC4 can degrade RIPK2 in a time-dependent manner and shows reduced lipophilicity and lower clearance in hepatocytes. However, the modest binding affinity between the warhead of PROTAC4 and RIPK2 requires a high dose to reach efficient RIPK2 degradation. To address this limitation, the researchers performed extensive medicinal chemistry optimization based on PROTAC 4 and identified PROTAC 6 (Figure2), which contains an...
Post a Comment
Read more